(Q45222914)

11 December 2017

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy (English)

1 reference

11 December 2017

1 reference

6

Arnaud Lacour

1 reference

11 December 2017

11

Patrick Vermersch

1 reference

11 December 2017

Olivier Outteryck

1

1 reference

11 December 2017

Jean-Claude Ongagna

2

1 reference

11 December 2017

Alain Duhamel

3

1 reference

11 December 2017

Hélène Zéphir

4

1 reference

11 December 2017

Nicolas Collongues

5

1 reference

11 December 2017

Marie-Céline Fleury

7

1 reference

11 December 2017

Anne-Sophie Berteloot

8

1 reference

11 December 2017

Frédéric Blanc

9

1 reference

11 December 2017

Marianne Giroux

10

1 reference

11 December 2017

Jérôme de Sèze

12

1 reference

11 December 2017

12 April 2012

1 reference

11 December 2017

1 reference

11 December 2017

259

1 reference

11 December 2017

11

1 reference

11 December 2017

2293-2298

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-012-6487-5

11 December 2017

0 references

cites work

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

A bootstrap resampling procedure for model building: Application to the cox regression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6487-5

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22527227

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22527227

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-012-6487-5

1 reference

Dimensions Publication ID

11 December 2017

1050128907

0 references

Fatcat ID

release_onoxousbtngjbpj2d6gdulp5fa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/onoxousbtngjbpj2d6gdulp5fa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference